Jefferies Upgrades Apellis Pharmaceuticals to Buy, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari upgraded Apellis Pharmaceuticals (NASDAQ:APLS) from Hold to Buy and increased the price target from $68 to $80, indicating a positive outlook on the company's stock.

February 05, 2024 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies upgraded Apellis Pharmaceuticals to Buy from Hold and raised the price target to $80 from $68.
An upgrade from Hold to Buy typically signals a strong bullish outlook on the stock by the analyst, suggesting an expectation of upward price movement. The increase in price target further reinforces this positive sentiment, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100